Ben Fidler

Senior Editor

Ben is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.

74 articles by Ben Fidler

Filter by Month:

First oral drug for spinal muscular atrophy approved by FDA
Aug. 7, 2020
Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes
Aug. 7, 2020
Trump tries to revamp drug supply chain with latest order
Aug. 6, 2020
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
Aug. 6, 2020
With first results, Novavax takes step forward in coronavirus vaccine race
Aug. 4, 2020
Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future
Aug. 4, 2020
Lilly to test COVID-19 antibody drug in unorthodox nursing home study
Aug. 3, 2020
J&J, beginning first human trial, aims for a 1-shot coronavirus vaccine
July 30, 2020
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
July 29, 2020
A Roche arthritis drug fails in COVID-19, casting doubt on a strained hypothesis
July 29, 2020
BioNTech, Pfizer pick a surprise coronavirus vaccine, follow Moderna into late-stage test
July 28, 2020
Moderna secures almost $500M more as it starts first large-scale US study of coronavirus vaccine
July 27, 2020
On eve of first big coronavirus vaccine study, trial leaders brace for 'unprecedented' task
July 24, 2020
EQRx, gearing up for a price war with big pharma, buys two cancer drugs
July 23, 2020
Coronavirus vaccine developers make case to Congress they can win public's trust
July 21, 2020
Oxford coronavirus vaccine spurs immune responses, appears safe on first look
July 20, 2020
New data from MeiraGTx help bolster J&J's gene therapy bet
July 17, 2020
A startup launches with big plans to develop antibody drugs for coronaviruses
July 16, 2020
Blueprint, eyeing an independent future, gets $775M in new Roche alliance
July 14, 2020
India clears a psoriasis drug for COVID-19, and a tiny US biotech's shares soar
July 13, 2020
Two patients die in now-halted study of Audentes gene therapy
June 26, 2020
Zogenix caps tumultuous ride with FDA OK for Dravet drug
June 26, 2020
In a surprise, UniQure sells its hemophilia gene therapy for $450M
June 25, 2020
Federal government accuses Regeneron of kickback scheme for top-selling drug
June 24, 2020
Merck strikes another neuroscience deal, tapping Yumanity for 2 brain drugs
June 24, 2020
Biogen loses patent dispute with Mylan, putting its top drug's future in doubt
June 18, 2020
AbbVie puts $60M into ex-Dendreon CEO's company in autoimmune drug pact
June 18, 2020
With latest Keytruda approval, Merck beats Bristol Myers to a new immunotherapy target
June 17, 2020
Lilly claims success in early breast cancer study, leaping past Pfizer
June 16, 2020
AstraZeneca signs new supply deals as coronavirus vaccine data nears
June 15, 2020
Moderna to start in July what could be first late-stage coronavirus vaccine trial
June 11, 2020
Regeneron brings first COVID-19 antibody 'cocktail' into human tests
June 11, 2020
AbbVie hands Genmab $750M in latest bid to grow cancer drug business
June 10, 2020
Drug regulators in agreement on coronavirus vaccine trials, FDA official says
June 9, 2020
AstraZeneca, already a leader in coronavirus vaccine race, steps up antibody drug work
June 9, 2020
Sarepta, with new data, plans final push for limb-girdle gene therapy
June 8, 2020
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
June 5, 2020
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
June 4, 2020
Biotech IPOs near last year's pace, despite COVID-19 pandemic
June 3, 2020
Eli Lilly starts first-ever trial of a COVID-19 antibody drug, speeding past rivals
June 1, 2020
How Merck seeks to catch up in the coronavirus drug race
June 1, 2020
With new Allogene data, same promise, questions surround 'off the shelf' CAR-T
May 29, 2020
Gilead puts $375M into Arcus in latest push to broaden cancer business
May 27, 2020
Merck makes COVID-19 drug plans clear with flurry of deals
May 26, 2020
Sunovion crowds a new group of Parkinson's drugs, with uncertain sales prospects
May 22, 2020
US secures supply of AstraZeneca, Oxford coronavirus vaccine, pledging more than $1B
May 21, 2020
AstraZeneca, Merck race past Clovis as PARPs break into prostate cancer
May 20, 2020
Bristol Myers, trailing Merck in lung cancer, finally wins FDA OK for immunotherapy combo
May 18, 2020
Moderna delivers first human data for a coronavirus vaccine
May 18, 2020
Safety questions linger as Pfizer preps Duchenne gene therapy for final test
May 15, 2020
Allogene gives first look at an 'off the shelf' cell therapy for lymphoma
May 13, 2020
Surprise setback for Bristol, Bluebird as FDA rejects cell therapy application
May 13, 2020
A closer look at the race to develop antibody drugs for COVID-19
May 12, 2020
Akebia, chasing FibroGen, nears FDA review with new anemia pill data
May 5, 2020
Moderna, with government cash, taps Lonza to make 1 billion doses of COVID-19 vaccine
May 1, 2020
AstraZeneca, racing past rivals, throws its weight behind Oxford's COVID-19 vaccine
April 30, 2020
Thrive, chasing Grail with a cancer blood test, finds tumors in seemingly healthy women
April 28, 2020
Another step for PARPs as AstraZeneca, Merck drug extends lives in prostate cancer
April 24, 2020
Why $120M for Affinivax may reflect a new view of vaccine makers
April 23, 2020
Seattle Genetics wins another speedy approval as FDA clears breast cancer drug
April 17, 2020
NIH spearheads broad partnership with drugmakers, regulators to speed COVID-19 therapies
April 17, 2020
Moderna's coronavirus vaccine plan may be possible, but a lot has to go in its favor
April 14, 2020
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
April 8, 2020
FDA's new Keytruda review is a step for genetic medicine, immunotherapy
April 7, 2020
Gilead to lean on Second Genome's microbiome work in $38M research pact
April 6, 2020
Fate inks $100M J&J pact for 'off-the-shelf' cancer cell therapies
April 3, 2020
Drugmakers await reckoning as doctors, patients make tough choices during pandemic
April 1, 2020
5 FDA approval decisions to watch in the 2nd quarter
March 30, 2020
Despite another delay, Intercept says its NASH drug remains on track
March 26, 2020
Lilly, Galapagos halt trials as coronavirus deepens impact on drug research
March 23, 2020
FDA maps out plan for trials as coronavirus starts to threaten drug research
March 18, 2020
Coronavirus led one biotech to pause a key trial, as more begin to follow
March 17, 2020
Fosun, Pfizer to help BioNTech join the mRNA race for a coronavirus vaccine
March 16, 2020
As coronavirus spreads, a biotech IPO squeaks through. Others may 'wait and see'
March 12, 2020